ArticleAntimicrobial agents and chemotherapy2016
Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- Modified Hevein-like Peptide fromPharmaceutics · 2025Article
- Development of citral-based hydrogel for the treatment of oral candidosis: in vitro and in vivo study.Clinical oral investigations · 2025Article
- In-vivo Studies on Sustained Release Systems for Delivering Antimycotics. A Systematic Review focused on Oral Candidiasis treatment.Journal of clinical and experimental dentistry · 2025Review
- Protective effect of histatin 5 and amphotericin B conjugated nanostructures in C. albicans challenged Swiss albino mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Novel Antimicrobial Protein Fibroblast Growth Factor 8 Accelerates Skin Wound Healing via Directly Inhibiting Bacteria and Activating Glycolysis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Antimicrobial Peptides Act-6 and Act 8-20 Derived from Scarabaeidae Cecropins Exhibit Differential Antifungal Activity.Journal of fungi (Basel, Switzerland) · 2025Article
- Reducing Functional Domain of Histatin 5 Improves Antifungal Activity and Prevents Proteolytic Degradation.Microorganisms · 2025Article
- Development of a Novel Histatin-5 Mucoadhesive Gel for the Treatment of Oral Mucositis: In Vitro Characterization and In Vivo Evaluation.AAPS PharmSciTech · 2023Article
- Peptides in Dentistry: A Scoping Review.Bioengineering (Basel, Switzerland) · 2023Article
- Pathogenesis and virulence ofVirulence · 2022Review
- Advanced Drug Delivery Platforms for the Treatment of Oral Pathogens.Pharmaceutics · 2022Review
- Long-Term Post-COVID-19 Associated Oral Inflammatory Sequelae.Frontiers in cellular and infection microbiology · 2022Article
- Drug delivery systems for oral disease applications.Journal of applied oral science : revista FOB · 2022Review
- Envisaging Antifungal Potential of Histatin 5: A Physiological Salivary Peptide.Journal of fungi (Basel, Switzerland) · 2021Review
- Natural Compounds for Preventing Ear, Nose, and Throat-Related Oral Infections.Plants (Basel, Switzerland) · 2021Review
- Biomaterials for the Prevention of Oral Candidiasis Development.Pharmaceutics · 2021Review
- Antimicrobial Polymer-Based Assemblies: A Review.International journal of molecular sciences · 2021Review
- Article
- Chemokine CCL28 Is a Potent Therapeutic Agent for Oropharyngeal Candidiasis.Antimicrobial agents and chemotherapy · 2020Article
- Bio- and Nanotechnology as the Key for Clinical Application of Salivary Peptide Histatin: A Necessary Advance.Microorganisms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Oral candidiasis (OC), caused by the fungal pathogen Candida albicans, is the most common opportunistic infection in HIV(+) individuals and other immunocompromised populations. The dramatic increase in resistance to common antifungals has emphasized the importance of identifying unconventional therapeutic options. Antimicrobial peptides have emerged as promising candidates for therapeutic intervention due to their broad antimicrobial properties and lack of toxicity. Histatin-5 (Hst-5) specifically has exhibited potent anticandidal activity indicating its potential as an antifungal agent. To that end, the goal of this study was to design a biocompatible hydrogel delivery system for Hst-5 application. The bioadhesive hydroxypropyl methylcellulose (HPMC) hydrogel formulation was developed for topical oral application against OC. The new formulation was evaluated in vitro for gel viscosity, Hst-5 release rate from the gel, and killing potency and, more importantly, was tested in vivo in our mouse model of OC. The findings demonstrated a controlled sustained release of Hst-5 from the polymer and rapid killing ability. Based on viable C. albicans counts recovered from tongues of treated and untreated mice, three daily applications of the formulation beginning 1 day postinfection with C. albicans were effective in protection against development of OC. Interestingly, in some cases, Hst-5 was able to clear existing lesions as well as associated tissue inflammation. These findings were confirmed by histopathology analysis of tongue tissue. Coupled with the lack of toxicity as well as anti-inflammatory and wound-healing properties of Hst-5, the findings from this study support the progression and commercial feasibility of using this compound as a novel therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.